Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied as duplicate or overlapping therapy by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

## Anthem's Duplicate-Therapy Denial on Semaglutide: The Real Mechanic

When Anthem (administered through its IngenioRx/CarelonRx pharmacy channel) issues a duplicate therapy denial for semaglutide, the rejection is rarely about the T2DM clinical criteria (HbA1c ≥6.5% within 12 months or established Type 2 diagnosis) — those are usually satisfied at the point of submission. The actual trigger is Anthem's concurrent drug utilization review (cDUR) edit, which flags semaglutide (Ozempic/Rybelsus) when the member has an active or recent claim for another GLP-1 receptor agonist (dulaglutide, liraglutide, tirzepatide, exenatide) or, increasingly, when a DPP-4 inhibitor (sitagliptin, linagliptin) is still on the active medication list. Anthem's Clinical UM Guideline CG-DRUG-119 (Glucagon-Like Peptide-1 Receptor Agonists) and the corresponding Medical Policy DRUG.00109 explicitly prohibit concurrent GLP-1 + GLP-1 and GLP-1 + DPP-4 combinations, citing redundant incretin mechanism and FDA labeling.

### Why the Denial Sticks Even With a Clean A1c

The pharmacy benefit adjudication runs the duplicate-therapy edit before clinical criteria are evaluated. So a member can meet every line of Anthem's published step-therapy and diagnostic logic and still receive an NDC-level reject (reject code 88 — DUR Reject Error, or 7X — duplicate therapy) at the CarelonRx point of sale. The prescriber's office often misreads this as a coverage criteria failure and resubmits the same PA — which fails identically.

### The Procedural Lever

Do not file a standard PA appeal. File a CarelonRx Coverage Determination request specifically invoking the duplicate-therapy override pathway, and attach: (1) a discontinuation note for the prior GLP-1 or DPP-4 with the exact stop date, (2) a washout attestation (Anthem expects ≥14 days for once-weekly agents, ≥7 days for daily), and (3) the prescriber's statement that the regimens are sequential, not concurrent. If the prior agent caused intolerance, cite that explicitly — Anthem's CG-DRUG-119 contains an intolerance exception buried in the criteria narrative.

If Anthem upholds on internal appeal, escalate under 29 CFR §2560.503-1 (ERISA full-and-fair-review disclosure) and demand the exact cDUR edit logic and the clinical rationale tying the denial to CG-DRUG-119. For fully-insured plans, file simultaneously with your state DOI — Anthem operates under separate Blue Cross licensees (BCBS GA, Anthem BCBS CA, Empire BCBS NY, etc.), and the state-level external review under the ACA (45 CFR §147.136) frequently overturns duplicate-therapy denials when the washout is documented. For self-funded ERISA plans, the Pinto v. Aetna (10th Cir. 2014) burden-shifting framework applies — Anthem must articulate why the clinical evidence supports the concurrent-use prohibition for this member, not boilerplate.

Tactical tip: Pull the member's CarelonRx claims history through the member portal before filing — if the prior GLP-1 shows a fill date within the last 30 days, the duplicate edit will re-fire regardless of the appeal. Time the resubmission to land at least 15 days after the last competing fill, and have the prescriber send the new e-script through Surescripts with a free-text SIG note: "Discontinue [prior agent] — initiate semaglutide per CG-DRUG-119 sequential therapy."

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.